All In Biotech

Drug Trial Radar · NCT02606630

[11C]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT 555 in Subjects With Relapsing Forms of Multiple Sclerosis

A [C-11]-PBR28 Positron Emission Tomography Study to Evaluate the Effect of ABT-555 on Central Nervous System Inflammation in Subjects With Relapsing Forms of Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Feb 8, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

4

Actual

Start

Oct 2015

Primary completion

Dec 2015

Study completion Dec 2015

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Nov 17, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This open-label positron emission tomography (PET) study is designed to determine the effect of ABT-555 on translocator protein expression level in participants with relapsing forms of multiple sclerosis.

Conditions

  • Multiple Sclerosis

Interventions

  • ABT-555Drug

    ABT-555 will be administered on Visit 4 in Part 2 only

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in translocator protein expressionTime frame: Day 0 and 109 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Site Reference ID/Investigator# 141463

    London, United Kingdom

  • Site Reference ID/Investigator# 141461

    Whitechapel, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.